Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development-Reference-Cited by-同舟云学术

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development

Published:2017-12-19 Issue:2 Volume:11 Page:123-146
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Faucette Stephanie¹,Wagh Santosh¹,Trivedi Ashit²,Venkatakrishnan Karthik¹,Gupta Neeraj¹

Affiliation:

1. Millennium Pharmaceuticals, Inc.; a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge Massachusetts USA

2. Clinical Pharmacology, Amgen Inc.; Thousand Oaks California USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cts.12527/fullpdf

Reference49 articles.

1. Next generation oncology drug development: opportunities and challenges;Gutierrez;Nat. Rev. Clin. Oncol,2009

2. Advancing clinical trials to streamline drug development.;Bates;Clin. Cancer Res.,2015

3. Ceritinib in ALK-rearranged non-small-cell lung cancer;Shaw;N. Engl. J. Med,2014

4. Seamless oncology-drug development;Prowell;N. Engl. J. Med.,2016

5. Expansion cohorts in first-in-human solid tumor oncology trials.;Theoret;Clin. Cancer Res,2015

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?;The AAPS Journal;2024-06-11

2. Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper;Clinical Pharmacology & Therapeutics;2024-05-16

3. Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach;CPT: Pharmacometrics & Systems Pharmacology;2024-01-30

4. Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer;Cancer Research Communications;2023-12-15

5. Recent Trends in Computer-aided Drug Design for Anti-cancer Drug Discovery;Current Topics in Medicinal Chemistry;2023-12